Plasma and intraperitoneal pharmacokinetics of ceftazidime/avibactam in peritoneal dialysis patients

被引:0
|
作者
al Jalali, Valentin [1 ]
Matzneller, Peter [1 ,2 ]
Pham, Anh Duc [3 ]
van Os, Wisse [1 ]
Woelfl-Duchek, Michael [1 ]
Sanz-Codina, Maria [1 ]
Vychytil, Andreas [4 ]
Reiter, Birgit [5 ]
Stimp, Thomas [5 ]
Zeitlinger, Markus [1 ,6 ]
机构
[1] Med Univ Vienna, Dept Clin Pharmacol, Vienna, Austria
[2] South Tyrol Hlth Syst ASDAA SABES, Serv Rheumatol, South Tyrol, Italy
[3] Leiden Univ, Leiden Acad Ctr Drug Res, Leiden, Netherlands
[4] Med Univ Vienna, Dept Med 3, Div Nephrol & Dialysis, Vienna, Austria
[5] Med Univ Vienna, Clin Dept Lab Med, Vienna, Austria
[6] Med Univ Vienna, Vienna Univ Hosp, Dept Clin Pharmacol, Waehringer Guertel 18-20, A-1090 Vienna, Austria
关键词
Avibactam; Ceftazidime; Intraperitoneal pharmacokinetics; Peritoneal dialysis; Pharmacokinetics; Pharmacometrics; PK/PD; Population pharmacokinetics; PHARMACODYNAMICS; AVIBACTAM; EXUDATE; SERUM; MODEL;
D O I
10.1016/j.cmi.2023.06.002
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: Peritonitis is a serious complication in patients undergoing automated peritoneal dialysis (APD) that increases morbidity and frequently disqualifies patients from the peritoneal dialysis programme. Ceftazidime/avibactam (CAZ/AVI) is a potential treatment option for APD patients with peritonitis caused by resistant Gram-negative bacteria, but limited data exist on systemic and target-site pharmacokinetics (PK) in patients undergoing APD. This study set out to investigate the PK of CAZ/AVI in plasma and peritoneal dialysate (PDS) of patients undergoing APD. Methods: A prospective, open-label PK study was conducted on eight patients undergoing APD. CAZ/AVI was administered as a single intravenous dose of 2 g/0.5 g over 120 minutes. APD cycles were initiated 15 hours after the study drug administration. Dense PDS and plasma sampling was performed for 24 hours after the start of administration. PK parameters were analysed with population PK modelling. Probability of target attainment (PTA) was simulated for different CAZ/AVI doses. Results: PK profiles of both drugs in plasma and PDS were similar, indicating that the two drugs are well suited for a fixed-dose combination. A two-compartment model best described the PK of both drugs. A single dose of 2 g/0.5 g CAZ/AVI led to concentrations that far exceeded the PK/PD targets of both drugs. In the Monte Carlo simulations, even the lowest dose (750/190 mg CAZ/AVI) achieved a PTA of >90% for MICs up to 8 mg/L (The European Committee on Antimicrobial Susceptibility Testing epidemiological cutoff value for Pseudomonas aeruginosa) in plasma and PDS. Discussion: On the basis of PTA simulations, a dose of 750/190 mg CAZ/AVI would be sufficient to treat plasma and peritoneal fluid infections in patients undergoing APD. (c) 2023 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.
引用
收藏
页码:1196.e1 / 1196.e7
页数:7
相关论文
共 50 条
  • [1] PHARMACOKINETICS OF INTRAPERITONEAL CEFTAZIDIME IN PATIENTS ON CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS
    RYCKELYNCK, JP
    DELIGNY, BH
    BATHO, JM
    VERGNAUD, M
    [J]. KIDNEY INTERNATIONAL, 1986, 30 (04) : 642 - 643
  • [2] PHARMACOKINETICS OF INTRAVENOUS AND INTRAPERITONEAL CEFTAZIDIME IN CHRONIC AMBULATORY PERITONEAL-DIALYSIS
    DEMOTESMAINARD, F
    VINCON, G
    RAGNAUD, JM
    MORLAT, P
    BANNWARTH, B
    DANGOUMAU, J
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 33 (05): : 475 - 479
  • [3] PHARMACOKINETICS OF CEFTAZIDIME IN PATIENTS UNDERGOING PERITONEAL-DIALYSIS
    TOURKANTONIS, A
    NICOLAIDIS, P
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1983, 12 : 263 - 267
  • [4] Intraperitoneal pharmacokinetics of vancomycin in patients on automated peritoneal dialysis
    Lam, Edwin
    Lien, Yi Ting Kayla
    Kraft, Walter K.
    Stickle, Douglas F.
    Piraino, Beth
    Zhang, Jingjing
    [J]. CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (03): : 649 - 657
  • [5] Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients
    Van Matre, E. T.
    Teitelbaum, I.
    Kiser, T. H.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (05)
  • [6] Pharmacokinetics of Intraperitoneal Vancomycin in Patients on Automated Peritoneal Dialysis
    Lam, Edwin
    Kraft, Walter K.
    Stickle, Douglas F.
    Piraino, Beth M.
    Zhang, JingJing
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 336 - 336
  • [7] PHARMACOKINETICS OF CEFTAZIDIME IN PATIENTS ON CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS
    STEA, S
    BACHELOR, T
    COOPER, M
    DESOUZA, P
    KOENIG, K
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1995, 6 (03): : 563 - 563
  • [8] Pharmacokinetics of intermittent intraperitoneal ceftazidime in the empirical therapy of dialysis-related peritonitis in continuous ambulatory peritoneal dialysis patients.
    Booranalertpaisarn, V
    Eiam-Ong, S
    Praditpornsilpa, K
    Chusil, S
    Tungsanga, K
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 384A - 385A
  • [9] INTRAPERITONEAL CEFTAZIDIME AS TREATMENT FOR PERITONITIS IN PATIENTS ON CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS
    RYCKELYNCK, JP
    DELIGNY, BH
    VERGNAUD, M
    DAPOGNY, C
    BATHO, JM
    LANDRU, I
    [J]. THERAPIE, 1987, 42 (01): : 37 - 39
  • [10] EVALUATION OF INTRAVENOUS AND INTRAPERITONEAL PHARMACOKINETICS OF DALBAVANCIN IN PERITONEAL DIALYSIS PATIENTS
    Van Matre, Edward
    Teitelbaum, Isaac
    Kiser, Tyree
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34 : 235 - 235